I am a Lecturer in Clinical Pharmaceutical Science in the Division of Pharmacy and Optometry. With my background in Pharmacy, I combine expertise in biochemistry and pharmacology to study the mechanisms of diseases caused by mitochondrial dysfunction.

I studied Pharmacy at the University of Nottingham, I became fascinated by the intricate molecular pathways that link metabolic dysfunction to the progression of diseases. My experience working in the pharmaceutical industry and hospital pharmacy led my interest towards applying scientific research to developing therapeutic interventions.  I completed my PhD under the supervision of Professor Mike Murphy at the MRC Mitochondrial Biology Unit, University of Cambridge. My PhD research focused on developing novel inhibitors of the mitochondrial enzyme succinate dehydrogenase, a key player in cellular energy production and key node in a number of diseases.

During my PhD, I became interested in translating my work, as it was relevant for treating ischaemia/reperfusion injury during heart attacks and inflammation. I carried out postdoctoral research at the University of Cambridge, working with Professor Thomas Krieg in the Department of Medicine. Here, I undertook work to understand the precise mechanisms of damage occurring in ischaemia/reperfusion injury and developed a novel therapeutic approach to combat this, which has shown to be effective in pre-clinical models of heart attack, ischaemic stroke and organ transplantation.

In January 2025, I took up my current Lectureship at the University of Manchester, to start my research program focused on understanding the role of mitochondrial metabolism and redox status in disease and identifying new therapeutic targets.

• Mitochondrial function in compromised oxygen environments
• Mitochondrial metabolism and redox status driving disease
• Mitochondria-targeted drug delivery
• Mitochondrial metabolite signalling